{"id":"open-label-run-in-esomeprazole","safety":{"commonSideEffects":[{"rate":"12-15%","effect":"Headache"},{"rate":"10-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-8%","effect":"Abdominal pain"},{"rate":"3-5%","effect":"Constipation"},{"rate":"3-5%","effect":"Flatulence"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Esomeprazole is the active S-enantiomer of omeprazole. It irreversibly inhibits the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, reducing both basal and stimulated gastric acid production. This mechanism provides rapid and sustained acid suppression, making it effective for treating acid-related gastrointestinal disorders.","oneSentence":"Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by blocking the H+/K+-ATPase enzyme in the stomach's parietal cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:36.342Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Zollinger-Ellison syndrome"},{"name":"Prevention of NSAID-induced ulcers"}]},"trialDetails":[{"nctId":"NCT03094416","phase":"PHASE4","title":"Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors","status":"COMPLETED","sponsor":"IBSA Institut Biochimique SA","startDate":"2018-07-30","conditions":"Hypothyroidism;Postablative","enrollment":66},{"nctId":"NCT02473640","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy","status":"COMPLETED","sponsor":"Theriva Biologics, Inc.","startDate":"2015-06","conditions":"Healthy Volunteers With Ileostomy","enrollment":15},{"nctId":"NCT00468559","phase":"PHASE3","title":"Phase 3/Safety & Efficacy of Esomeprazole in Infants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-04","conditions":"Gastroesophageal Reflux Disease (GERD)","enrollment":98},{"nctId":"NCT00730665","phase":"PHASE2","title":"Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-01","conditions":"Gastroesophageal Reflux Disease","enrollment":81}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Open Label Run In Esomeprazole","genericName":"Open Label Run In Esomeprazole","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by blocking the H+/K+-ATPase enzyme in the stomach's parietal cells. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}